A Flow of New Options for Relapsed and Refractory Hodgkin Lymphoma

patientpower has 2377 videos Subscribe Here

Description: Can a new antibody drug conjugate, ADCETRIS (brentuximab vedotin), be the foundation of new combination therapies for patients with relapsed or refractory Hodgkin lymphoma? Dr. Joseph Connors, a leader in lymphoma treatment from Vancouver, Canada, discusses the possibilities that could bring new hope to patients with this rare condition. His belief is new research could have promising benefits for patients living with the condition today.
Shared By : patientpower
Posted on : 10/13/12
Added : 5 years ago
Category : Lymphoma